| Title |
What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects
|
|---|---|
| Published in |
Drug Safety, June 2018
|
| DOI | 10.1007/s40264-018-0681-z |
| Pubmed ID | |
| Authors |
Rike van Eekeren, Leàn Rolfes, Andries S. Koster, Lara Magro, Gurumurthy Parthasarathi, Hussain Al Ramimmy, Tim Schutte, Daisuke Tanaka, Eugène van Puijenbroek, Linda Härmark |
| Abstract |
Adverse drug reactions (ADRs) can cause serious health problems, as shown in studies about drug-related hospitalizations. To build knowledge of and raise awareness about ADRs among healthcare professionals, more education in the field of ADRs and pharmacovigilance (PV) is needed. No standard exists for teaching PV at universities for medical, pharmacy, dentistry and nursing students, so a core curriculum needs to be developed to teach important aspects of PV to students. In September 2016, a stakeholders' meeting was initiated on behalf of the World Health Organization (WHO) and organized by the Netherlands Pharmacovigilance Centre Lareb. This meeting addressed and agreed on the PV competencies students need to develop and what key aspects of the subject should be taught. Five key aspects were identified: understanding the importance of PV in the context of pharmacotherapy, and preventing, recognizing, managing and reporting ADRs. Since time and resources for PV education are limited, elements of the WHO PV core curriculum for university teaching were designed to be integrated into existing courses but can be used as a stand-alone programme. The basis of and outline for the WHO PV core curriculum for university teaching are addressed in this paper. It is expected that PV competencies for students are vital for their contribution to safe use of medicines in the future. In addition, this article aims to stimulate discussion on this subject and promote collaboration between universities, national PV centres and other stakeholders to integrate key aspects of PV in their educational programmes. |
X Demographics
The data shown below were collected from the profiles of 72 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 15 | 21% |
| Colombia | 7 | 10% |
| Spain | 5 | 7% |
| Sweden | 5 | 7% |
| United States | 4 | 6% |
| United Kingdom | 3 | 4% |
| Mexico | 2 | 3% |
| Panama | 2 | 3% |
| Ecuador | 2 | 3% |
| Other | 11 | 15% |
| Unknown | 16 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 61 | 85% |
| Practitioners (doctors, other healthcare professionals) | 6 | 8% |
| Scientists | 4 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 122 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 15% |
| Student > Bachelor | 16 | 13% |
| Researcher | 7 | 6% |
| Other | 6 | 5% |
| Lecturer | 6 | 5% |
| Other | 24 | 20% |
| Unknown | 45 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 25 | 20% |
| Nursing and Health Professions | 16 | 13% |
| Medicine and Dentistry | 16 | 13% |
| Business, Management and Accounting | 3 | 2% |
| Social Sciences | 2 | 2% |
| Other | 12 | 10% |
| Unknown | 48 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 49. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2019.
All research outputs
#875,127
of 25,732,188 outputs
Outputs from Drug Safety
#65
of 1,872 outputs
Outputs of similar age
#18,800
of 342,560 outputs
Outputs of similar age from Drug Safety
#4
of 21 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,872 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,560 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.